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Where next?
Overview
Adherence….?
DEFINITION
‘The extent to which a 
person’s behaviour 
corresponds with the agreed 
recommendations from a 
healthcare provider’
…. AFFECTS US ALL
92% of new year resolutions fail
 25% eat 5 fruit & veg daily
 37% maintain a BMI <25
76% drink 14 units alcohol/ wk or less
Respiratory Disease 
RCTs have repeatedly demonstrated the 
value of licensed COPD and asthma 
therapies
↓ Symptom burden
↑ Quality of Life
↔ Maintainance or slowing of disease 
progression
But …. In well controlled, highly selected 
populations, and in the shorter term 
Sanduzzi et al., 2014
Adherence to treatment and treatment components 
 WHO (2003) chronic conditions [50%]
Bronchiectasis/COPD/asthma/CF [30-
65%]
 Home nebuliser therapy [44% -50%]
Long term Oxygen therapy [40-70%] 
Gauthier et al (2018)
Increasing age and ambulatory O2 predicted 
adherence
60% adherence overall
Heutzch et al, 2012
Poor 
patient 
education
Social 
determinants
Complex 
dosing 
regimens
Disruption 
to daily 
routine
Lack of 
positive 
reinforceme
nt
Comorbidity
Adherence
Cochrane Database of Systematic Reviews Interventions to 
improve adherence to inhaled steroids for asthma (Review) 
Normansell R, Kew KM, Stovold E (2017)
11%↑
20%↑ 4%↑
Recommendations for future studies
 Use validated tools for outcome measurement, such as the Asthma Control Test (ACT), the 
Asthma Control Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ)
 Provide adequate details regarding baseline severity among participants. 
 Include some form of blinding or active control. 
Trialists to prespecify a threshold for ’acceptable’ adherence and to perform a dichotomous 
analysis of those achieving this level and those not achieving it
Validated measures for adherence
Morisky scale 
Do you sometimes forget to take your high blood pressure pills?
Over the past 2 weeks, were there any days when you did not take your high blood pressure medicine?
Have you ever cut back or stopped taking your medication without telling your doctor because you felt 
worse when you took it?.
When you travel or leave home, do you sometimes forget to bring along your medications?.
Did you take your high blood pressure medicine yesterday? 
When you feel like your blood pressure is under control, do you sometimes stop taking your medicine?
Taking medication everyday is a real inconvenience for some people. Do you ever feel hassled about 
sticking to your blood pressure treatment plan?
How often do you have difficulty remembering to take all your blood pressure medication?
Highly adherent 8 on the scale, 
Medium adherers with a score of 6 to <8, 
Low adherers with a score of <6 on scale
Sensitivity 93% 
Specificity 53%
The phases of adherence outlined in the ABC taxonomy
Adapted from Vrijens et al. (2012)
Although asthma medications 
were among the higher 
dispensed-prescriptions within 
the study, approximately one-
quarter of patients prescribed 
new asthma therapy failed to 
collect their first prescription
Primary non-adherence to newly prescribed medications. 
Patients aged 19 and over
Adherence measures
Self report
 Pharmacy refill
 Manual dose/pill count
MPR – does the patient collect the 
prescription
Electronic data – gives detail about 
variation in adherence
Conclusion
 Adherence is low
 Clinicians lack accurate methods to assess 
the issue
 Novel approaches to data analysis may 
aid understanding
 Digital technologies hold promise to 
overcome these barriers to care
Variation as a marker of adherence – early analogies 
with studies on blood pressure
Medication adherence and visit-to –
visit variability of systolic blood 
pressure in African Americans with 
chronic kidney disease in the AASK 
Trial
Hong et al J Hum Hypertens. 2016 Jan; 30(1): 
73–78.
Use of electronic data in adherence measurement?
Poor 
adherence?
Good 
adherence
Evaluating 
adherence and 
variation 
measures in Cystic 
Fibrosis
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White et al Eur Resp Journal, 2017
CoVFEV1, Number of medications, BMI
Digital Maturity Self-Assessment Survey (NHS England, 2016)
Challenges in maintaining 
anonymity and data security 
for data in transit and stored 
data are also a concern
Only 25% of the Sustainability 
and Transformation 
Partnership (STPs) with at 
least one trust with a high 
level of digital maturity (ie
overall score above 80)
Whether providers have staff with the digital skills needed
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What might work?
Reported adherence rates in CF are as low 
as 40-50%
In our own adult patient (n = 410) 
adherence is 63% (medication possession 
ratio) White et al (2017)
On-line adherence programmes for adults 
with CF have not yet been fully evaluated
We aimed to determine the impact on 
adherence of a web-based intervention for 
adults with CF 
Phase 2 (Module development)
 On-line modules developed
 40 video stories filmed and embedded giving reasons to 
change and motivations to take treatment eg
– Parenthood
– Further study
– Availability for new treatments
Development
Interactive material
Integrated ‘drag &            
drop’, games, quiz
 Nutrition
 Pancreatic enzyme 
replacement therapy
 Vitamins
 Airways & 
treatments
 Antibiotics
 Liver disease
3rd phase - RCT design
Usual care or web-based intervention (n=100)
Participants issued with tablet technology 
Granted structured access over 12 months
Modules released at intervals
Access tracked on-line
Facility to gather participant feedback on the system
Results
Data collected at baseline, 6 months and 1 year 
 Adherence (Medication possession ratio)*
 Knowledge questionnaire*
 QoL (CFQ-R)*
 Anthropometric data
 Respiratory function [FEV1(%), FVC(%), FEV1 rate of decline (% )and coefficient 
variation FEV1 (%)
 Fat soluble vitamin status
* Collected at baseline and 1 year only
Subject Characteristics at baseline
N=100 Intervention Control P-value
Gender (male) 28 (51.6%) 15 (51.7%) 0.82
Age (years) 27.5 (±6.8) 31.8 (±9.1) 0.01
Pseudomonas 37 (75.5%) 33 (64.7%) 0.831
CFRD (check) 19 (39.5%) 17 (33.3%) 0.54
Genotype
DF508/DF508
DF508/Other
Other/Other
30/15/4
61%/31%/8%
33/13/5
65%/25%/10%
0.84
FEV1(%) 47.8 (±22.2)% 56.5(±23.0)% 0.06
BMI (kg/m2) 21.1 (±2.9) 24.5 (±5.1) <0.001
Adherence at 
baseline and end 
of study
C CC CI I I I
Lung function
No changes in 
lung function, 
variation in lung function or 
rate of lung decline 
Iv days
BMI
above that of controls
Adjusted for BMI, Lung function and IV days at baseline
Knowledge
Significant increase 
in knowledge in 
intervention group 
compared to 
controls (p=0.046)
Engagement with the platform
TOTAL NUMBER OF TIMES MODULE 
COMPLETED
MODULE COMPLETIONS PER 
PARTICIPANT
24% of participants 
did not access the 
platform
A, Patient with late initiation but good 
implementation.
B, Patient with suboptimal implementation 
(missed single and consecutive doses, 
large variability in timing of drug intakes).
C, Patient with excellent implementation 
but short persistence (early 
discontinuation).
Where next?
Electronic monitoring
CFHealthHub: Development and evaluation of an intervention to 
support adherence to treatment in adults with Cystic Fibrosis
The aim of the programme is to develop and evaluate a complex 
behaviour change intervention (BCI) to support medication adherence 
for adults with Cystic Fibrosis (CF). 
The BCI includes the development of a web portal, CFHealthHub, to 
capture adherence data from patients’ nebulisers and display this to 
clinicians and patients with CF (PWCF). 
CFHealthHub will facilitate a range of evidence-based interventions 
including problem solving and setting implementation plans to increase 
treatment adherence.
Patient engagement strategies
Synchronised dose 
for multiple multiple
drug therapy
Self-management 
self-monitoring & 
problem solving
Use of action plans 
(better knowledge  
of the importance of 
early intervention)
Improved 
communication –
providing a rationale
Knowledge alone 
rarely successful
Access to a secondary care 
clinical record?
Mobile apps - Umotif
Conclusion
New technologies – used selectively when patients need and 
require them
Collaborations – Apple Health – sending of data to the clinical 
record - addressing travel, out-patient waiting times and prompting 
early interventions 
Using electronic data to identify those patients who will benefit 
most 
